

'It's better to treat a COVID patient than a HIV patient': using feminist participatory research to assess women's challenges to access HIV care in Indonesia during the COVID-19 pandemic (Penulis Pertama dan Korespondensi), Scopus Q4

<https://journals.sagepub.com/doi/full/10.1177/20499361211064191>

[Submission and revision in the system]

The screenshot shows the 'Author Dashboard' with a sidebar menu containing '2 Manuscripts with Decisions', 'Start New Submission', and '5 Most Recent E-mails'. The main area is titled 'Manuscripts with Decisions' and contains a table with the following data:

ACTION	STATUS	ID	TITLE	SUBMITTED	DECISIONED
	ADM: Barthwal, Shivani ADM: Bedi, Hemali	TAID-21-088.R1	"It's better to treat a COVID patient than a HIV patient": Using Feminist Participatory Research to Assess Women's Challenges to Access HIV Care in Indonesia During the COVID-19 Pandemic	05-Nov-2021	15-Nov-2021
	<ul style="list-style-type: none"> <li>Accept (15-Nov-2021)</li> </ul> Archiving completed on 04-Dec-2022 <a href="#">view decision letter</a> <a href="#">Contact Journal</a>		Files Archived		
a revision has been submitted (TAID-21-088.R1)	ADM: Barthwal, Shivani ADM: Bedi, Hemali	TAID-21-088	"It's better to treat a COVID patient than an HIV patient": The Challenges of Accessing HIV Care in Indonesia in Pandemic Times	22-Jul-2021	18-Oct-2021
	<ul style="list-style-type: none"> <li>Major Revision (18-Oct-2021)</li> <li>a revision has been submitted</li> </ul> Archiving completed on 04-Dec-2022 <a href="#">view decision letter</a>		Files Archived		

[corresponding authors from editors]

The screenshot shows an email titled 'Decision Letter (TAID-21-088)' from TAIInfectiousDisease@sagepub.co.uk to najem240783@gmail.com. The subject is 'Therapeutic Advances in Infectious Disease - Decision on Manuscript ID TAID-21-088'. The body of the email reads:

Dear Mrs Najmah,

Manuscript ID TAID-21-088 entitled "It's better to treat a COVID patient than an HIV patient": The Challenges of Accessing HIV Care in Indonesia in Pandemic Times" which you submitted to Therapeutic Advances in Infectious Disease, has been reviewed. The comments of the reviewer(s) are included at the bottom of this letter.

The reviewer(s) have recommended publication, but also suggest some revisions to your manuscript. Therefore, I invite you to respond to the reviewer(s)' comments and revise your manuscript.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/taid> and enter your Author Centre, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please also highlight the changes to your manuscript within the document by using the track changes mode in MS Word or by using bold or colored text.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Centre.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you make to the original manuscript. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the reviewer(s).

**IMPORTANT:** Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to Therapeutic Advances in Infectious Disease, your revised manuscript should be uploaded as soon as possible. If it is not possible for you to submit your revision in a reasonable amount of time, we may have to consider your paper as a new submission.

Once again, thank you for submitting your manuscript to the Therapeutic Advances in Infectious Disease and I look forward to receiving your revision.

Sincerely,

Andrés F. Henao-Martínez, MD  
 Editor-in-Chief  
 Therapeutic Advances in Infectious Disease  
 TAIInfectiousDisease@sagepub.co.uk

Reviewer(s) Comments to Author:

Reviewer: 1

Comments to the Author

Comments

The authors present a study about discrimination and stigma against women during the COVID-19 pandemic in Sumatra. This study is relevant for human rights advocacy and to highlight the lack of access to healthcare. For these reasons the authors should address some issues to support their data.

Major Issues

Study groups and their results are not clear, first it is mentioned that two aspects were studied: exploring stigma of HIV in women and exploring the experiences of women with HIV when they try to access health services during COVID-19 pandemic. To achieve the goals, two study groups were established. The first group is clear: women with HIV, but the second group only indicates women who experienced stigma when they were tested for COVID-19, it does not indicate whether they were women with HIV or women without HIV, that is why the authors need to define the second group clearly. Also, it is not mentioned in the inclusion criteria.

By the way, figure 5 shows the perception of good mothers by a non-HIV woman, but it is not clear whether non-HIV women participated in this study.

In the manuscript it is mentioned that the study focused on the narratives of twenty women living with HIV, but only five narratives are shown (although on page 2, line 54 says three stories would be included) and the results of the rest of the participants are not discussed. Besides, the information in Table 1 is not clear, the differences between the X and V of the columns is confusing, you should discuss results shown in Table 1 to visualize the experience of the twenty participating women, their perception of HIV stigma and the difficulty accessing health services during the COVID-19 pandemic.

Authors need to be careful in their methods and include in the manuscript how they avoided biases in the women's perspective, as well as persuasion by researchers.

A more specific subtitle is suggested, such as: Women's Challenges of Accessing HIV Care in Indonesia in Pandemic Times.

Reviewer: 2

Comments to the Author

Reviewer comments:

1. Background:

Although there is no much data published on Stigma and Discrimination, it would be informative if the authors could give some background with evidence about the current stigma and discrimination situation. Proposed source: Stigma Index by Spiritia foundation.

2. The study does not show the timeline of when it was done, which year, for how long?

3. Sample size

a. How was the sample size was calculated?

4. How were the FDG participants allocated to groups? Was it based on age, HIV status or they share other characteristics (inclusion criteria

5. Data collection tools: were these pre tested before the study?

6. Analysis:

a. Why the analyses only mention one person per analysis not group analysis/group's conclusion.

b. Was a software used or the data were analyzed manually?

c. Content analysis was used, was it a conceptual analysis or relational analysis

d. Was the translation and transcription done, who did these

Editor(s) Comments to Author:

Associate Editor

Comments to Author:

The Editors have reviewed your manuscript, and agree with the reviewers that the data presented is valuable. However, in addition to the reviewer's critique, we would like to suggest a number of changes to improve the suitability of the article for a scientific audience.

1. Title: Please revise your title to state the research question, study design, and location. This is the preferred format for the journal.

2. Abstract: We recommend a structured abstract that states the objective of the study, along with a summary of the key data or arguments and an overall conclusion. Please use the following headings to structure your abstract: Background; Objectives; Design; Methods; Results; Conclusion.

3. Table 1: Please consider revising table 1 to present less information. We are concerned that including this amount of detail in the table risks identifying the study participants.

One attachment • Scanned by Gmail



Najmah Usman <najem240783@gmail.com>  
to TAIInfectiousDisease, bcc: Sharyn

Tue, Oct 19, 2021, 5:43 PM



Dear editorial team

Thank you very much for the notification. thank you for rich feedback

What is the deadline for this revision?

We will revise it soon

Najmah

...

TAID-21-088: regarding due date > Inbox x



**TA Infectious Disease** <TAInfectiousDisease@sagepub.co.uk>  
to me

Thu, Oct 21, 2021, 1:59 PM ☆ ↶ ⋮

Dear Dr Usman,

Thank you for your email.

The deadline for the submission is 18 December.

Let me know if you need any other help.

Thanks and Regards,  
Ipsa Suyal  
TAI

[communication with another co-author, Prof Sharyn Graham Davies]

**Najmah Usman** <najem240783@gmail.com>  
to Sharyn

Tue, Oct 19, 2021, 6:02 AM ☆ ↶ ⋮

Mom

our paper on stigma and discrimination is accepting with revision

thank you for your support

Najmah

...

3 Attachments • Scanned by Gmail



[production of manuscript for online publication in SAGE]

Therapeutic Advances in Infectious Disease Next steps for your article (TAID-21-088.R1)



> Inbox x

**Therapeutic Advances in Infectious Disease** <onbehalf@manuscriptcentral.com>  
to me, sharyn.davies, 2000149, tom.davies16

Tue, Nov 16, 2021, 9:58 PM ☆ ↶ ⋮

16-Nov-2021

Dear Mrs Najmah Najmah,

TAID-21-088.R1 - "It's better to treat a COVID patient than a HIV patient": Using Feminist Participatory Research to Assess Women's Challenges to Access HIV Care in Indonesia During the COVID-19 Pandemic

Your manuscript will shortly be exported to SAGE's production system. The next steps are as follows: -

1. You will receive an email from [openaccess@sagepub.com](mailto:openaccess@sagepub.com) asking you to complete the open access process for your article through the SAGE Open Access Portal in the next 7 working days
2. Follow the link in the email to: -

2. Follow the link in the email to: -

- View the article processing charge (APC)\* due for your article. The current APC rate can be found on the journal's SAGE homepage. If you have been informed that your article will receive a discount or waiver, you will be able to see that it has been applied in the portal
- Complete the Open Access Contributor Agreement so that SAGE can proceed with the publication of your article
- Pay the open access processing charge (APC)\*, if applicable. You may pay the APC yourself or nominate another bill payer to take responsibility for the payment through the portal. Payment can be made via credit/debit card or via wire/bank transfer

3. You will receive proofs of your article from the journal's Production Editor. Please allow at least 2 weeks to receive proofs. These should be checked thoroughly and returned promptly.

Once the steps have been completed, your article will be published open access on the journal website.

Please look out for the next email from [openaccess@sagepub.com](mailto:openaccess@sagepub.com) asking you to complete the open access process and act promptly. We are unable to proceed with publication of your article until the steps have been completed.

Please only contact us if you have not received the open access process email after 7 working days have passed.

3. You will receive proofs of your article from the journal's Production Editor. Please allow at least 2 weeks to receive proofs. These should be checked thoroughly and returned promptly.

Once the steps have been completed, your article will be published open access on the journal website.

Please look out for the next email from [openaccess@sagepub.com](mailto:openaccess@sagepub.com) asking you to complete the open access process and act promptly. We are unable to proceed with publication of your article until the steps have been completed.

Please only contact us if you have not received the open access process email after 7 working days have passed.

With best wishes,

SAGE Open Access Team

\*The APC is subject to tax where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when entering the billing details. Please see further details here: <https://us.sagepub.com/en-us/nam/faqs#tax>. The currency in which the APC is charged is determined by the geographical region of the corresponding author and cannot be changed by the payer of the APC.

**Decision Letter (TAID-21-088.R1)**

**From:** TAIInfectiousDisease@sagepub.co.uk  
**To:** najem240783@gmail.com  
**CC:**  
**Subject:** Therapeutic Advances in Infectious Disease - Decision on Manuscript ID TAID-21-088.R1  
**Body:** 15-Nov-2021

Dear Mrs Najmah,

It is a pleasure to accept your manuscript entitled "It's better to treat a COVID patient than a HIV patient": Using Feminist Participatory Research to Assess Women's Challenges to Access HIV Care in Indonesia During the COVID-19 Pandemic" in its current form for publication in Therapeutic Advances in Infectious Disease. The comments of the reviewer(s), if any, who reviewed your manuscript are included at the foot of this letter.

We value your feedback! If you have any comments on the publishing process, please do let us know.

To boost the visibility of our published papers, we promote all articles on our Twitter channel (@xxx) as soon as they are published. If you have a Twitter handle, please do send it to us so we can include you in our Tweets. We also encourage authors to share these tweets, as well as the article, to promote their work and widen the publication's reach.

Thank you again for your fine contribution. On behalf of the Editors of Therapeutic Advances in Infectious Disease, we look forward to your continued contributions to the Journal.

Sincerely,  
Dr Shema Tariq  
Associate Editor

Andrés Henao-Martinez  
Editor-in-Chief  
Therapeutic Advances in Infectious Disease  
TAIInfectiousDisease@sagepub.co.uk

Reviewer(s)' Comments to Author:

Reviewer: 1  
Comments to the Author  
Some significant changes have been made to the manuscript based on the previous review. The authors have adequately addressed my concerns.

Editor(s)' Comments to Author:  
Associate Editor  
Comments to Author:  
Many thanks for your revisions. Please amend any reference to HIV-positive women/mothers and to disclose/disclosure. In line with our commitment to stigma-free language, we encourage all authors to use the terms women living with HIV (and women without HIV), and share/tell (rather than disclose).

**Date Sent:** 15-Nov-2021

15-Nov-2021

Dear Mrs Najmah,

It is a pleasure to accept your manuscript entitled "'It's better to treat a COVID patient than a HIV patient": Using Feminist Participatory Research to Assess Women's Challenges to Access HIV Care in Indonesia During the COVID-19 Pandemic" in its current form for publication in Therapeutic Advances in Infectious Disease. The comments of the reviewer(s), if any, who reviewed your manuscript are included at the foot of this letter.

We value your feedback! If you have any comments on the publishing process, please do let us know.

To boost the visibility of our published papers, we promote all articles on our Twitter channel (@xxx) as soon as they are published. If you have a Twitter handle, please do send it to us so we can include you in our Tweets. We also encourage authors to share these tweets, as well as the article, to promote their work and widen the publication's reach.

Thank you again for your fine contribution. On behalf of the Editors of Therapeutic Advances in Infectious Disease, we look forward to your continued contributions to the Journal.

Sincerely,

Dr Shema Tariq  
Associate Editor

Andrés Henao-Martínez  
Editor-in-Chief  
Therapeutic Advances in Infectious Disease  
[TAInfectiousDisease@sagepub.co.uk](mailto:TAInfectiousDisease@sagepub.co.uk)

Reviewer(s)' Comments to Author:

Reviewer: 1

Comments to the Author

Some significant changes have been made to the manuscript based on the previous review. The authors have adequately addressed my concerns.

Editor(s)' Comments to Author:

Associate Editor

Comments to Author:

Many thanks for your revisions. Please amend any reference to HIV-positive women/mothers and to disclose/disclosure. In line with our commitment to stigma-free language, we encourage all authors to use the terms women living with HIV (and women without HIV), and share/tell (rather than disclose).

[asking changing email from my gmail [-najem240783@gmail.com](mailto:-najem240783@gmail.com) to official email from university, najmah@fkm.unsri.ac.id]



**Najmah Usman** <najem240783@gmail.com>  
to najmah, Bharti, TA, TAI ▾

Tue, Oct 4, 2022, 3:29 PM ☆ ↶ ⋮

Dear Bharti,

I want to ask about the email that I used for my corresponding author. My university asked me to use my official email for claiming this paper as my work for Professor degree later in Indonesia, do you think it is possible to do it, Bharti, thank you for your help

[najmah@fkm.unsri.ac.id](mailto:najmah@fkm.unsri.ac.id)

**'It's better to treat a COVID patient than a HIV patient': using feminist participatory research to assess women's challenges to access HIV care in Indonesia during the COVID-19 pandemic**

...



**Bharti Koul** <Bharti.Koul@sagepub.in>  
to Hemali, me, TA, TAI, najmah ▾

Oct 4, 2022, 4:31 PM ☆ ↶

Dear Najmah,

Thank you so much for your email, we shall update your email id to [najmah@fkm.unsri.ac.id](mailto:najmah@fkm.unsri.ac.id).

Dear Uma,

Could you please update the email id as Najmah has mentioned, please do let me know in case you have any questions.

Best,  
Bharti

Bharti Koul  
Content Manager – Journals Production (Global Services)  
SAGE Publications India Pvt Ltd.

...

...



**najmah unsri** <najmah@fkm.unsri.ac.id>  
to Hemali, TA, Bharti, me, TAI ▾

Oct 4, 2022, 6:57 PM ☆

Dear Bharti and Shivani

thank you for your quick response. It would be really appreciated if you could change this corresponding author [najem240783@gmail.com](mailto:najem240783@gmail.com) to [najmah@fkm.unsri.com](mailto:najmah@fkm.unsri.com)

